Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Thursday.

CPRX has been the topic of several other research reports. HC Wainwright set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 22nd. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a report on Monday, August 13th. Oppenheimer set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. Cantor Fitzgerald started coverage on shares of Catalyst Pharmaceuticals in a report on Friday, September 21st. They set an “overweight” rating on the stock. Finally, Piper Jaffray Companies started coverage on shares of Catalyst Pharmaceuticals in a report on Friday, September 7th. They set an “overweight” rating and a $5.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.61.

CPRX opened at $3.31 on Thursday. Catalyst Pharmaceuticals has a 1-year low of $2.18 and a 1-year high of $4.51. The firm has a market cap of $357.05 million, a price-to-earnings ratio of -15.76 and a beta of 1.46.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.02. Equities analysts forecast that Catalyst Pharmaceuticals will post -0.29 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of CPRX. MetLife Investment Advisors LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth $157,000. New York State Common Retirement Fund grew its stake in shares of Catalyst Pharmaceuticals by 47.6% in the 1st quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock worth $179,000 after acquiring an additional 24,200 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter worth $230,000. Lido Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 46.5% in the 2nd quarter. Lido Advisors LLC now owns 87,506 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 27,766 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Catalyst Pharmaceuticals by 34.7% in the 2nd quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock worth $283,000 after acquiring an additional 23,383 shares in the last quarter. Hedge funds and other institutional investors own 51.49% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Further Reading: Buyback

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.